Scatter Plot from Scientific Research

Neutralizing ID50 titers against sera from individuals who received a BA.4/5 bivalent booster vaccination after 3 doses of an mRNA vaccine. Lines indicate geometric mean across variants or designs. The BA.4/5 bivalent booster vaccine was evaluated on its ability to neutralize variants circulating in the 4 months prior to the creation of the booster vaccines (BA.2.75, BQ.1, BQ.1.1, and XBB). Designed spike constructs on the background of variants circulating prior to the vaccine foreshadowed the antibody escape observed against variants that emerged following the bivalent booster approval (XBB.1, XBB.1.5, and CH.1.1). Statistical significance was assessed using the Wilcoxon rank-sum test.

DOI